Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Gross Margin (2018 - 2023)

Serina Therapeutics (SER) has disclosed Gross Margin for 6 consecutive years, with 1.78% as the latest value for Q4 2023.

  • Quarterly Gross Margin fell 8572.0% to 1.78% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 3.24% through Dec 2023, down 5853.0% year-over-year, with the annual reading at 3.24% for FY2023, 5853.0% down from the prior year.
  • Gross Margin hit 1.78% in Q4 2023 for Serina Therapeutics, down from 117.24% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 117.24% in Q3 2023 to a low of 1.78% in Q4 2023.
  • Historically, Gross Margin has averaged 76.17% across 5 years, with a median of 85.83% in 2019.
  • Biggest YoY gain for Gross Margin was 7280bps in 2023; the steepest drop was -8572bps in 2023.
  • Year by year, Gross Margin stood at 85.61% in 2019, then grew by 13bps to 96.84% in 2020, then decreased by -1bps to 96.3% in 2021, then fell by -9bps to 87.5% in 2022, then plummeted by -98bps to 1.78% in 2023.
  • Business Quant data shows Gross Margin for SER at 1.78% in Q4 2023, 117.24% in Q3 2023, and 57.14% in Q2 2023.